{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T19:48:43Z","timestamp":1776282523698,"version":"3.50.1"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"vor","delay-in-days":550,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.exphem.2023.01.006","type":"journal-article","created":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T02:31:10Z","timestamp":1676341870000},"page":"38-47.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["The levels of serum soluble CD86 are correlated with the expression of CD86 variant 3 gene and are prognostic indicators in patients with myeloma"],"prefix":"10.1016","volume":"121","author":[{"given":"Ryosuke","family":"Kinoshita","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariko","family":"Ishibashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3753-9862","authenticated-orcid":false,"given":"Hiroshi","family":"Handa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoichi","family":"Imai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norina","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3899-6603","authenticated-orcid":false,"given":"Shigeki","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mika","family":"Sunakawa-Kii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuta","family":"Kaito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshio","family":"Asayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norio","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junji","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Odajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1234-417X","authenticated-orcid":false,"given":"Hiroki","family":"Sugimori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koiti","family":"Inokuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1782-4375","authenticated-orcid":false,"given":"Hideto","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2023.01.006_bib0001","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"van de Donk","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.exphem.2023.01.006_bib0002","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(14)60493-1","article-title":"Multiple myeloma","volume":"385","author":"R\u00f6llig","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.exphem.2023.01.006_bib0003","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.3324\/haematol.2020.247015","article-title":"Multiple myeloma: the (r)evolution of current therapy and a glance into future","volume":"105","author":"Gulla","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2023.01.006_bib0004","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/4812637","article-title":"The evolution of prognostic factors in multiple myeloma","volume":"2017","author":"Hanbali","year":"2017","journal-title":"Adv Hematol"},{"key":"10.1016\/j.exphem.2023.01.006_bib0005","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.beha.2005.01.012","article-title":"Prognostic features of multiple myeloma","volume":"18","author":"San Miguel","year":"2005","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.exphem.2023.01.006_bib0006","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1093\/annonc\/mdn677","article-title":"Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy","volume":"20","author":"Ennishi","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.exphem.2023.01.006_bib0007","doi-asserted-by":"crossref","first-page":"785","DOI":"10.3324\/haematol.2016.150896","article-title":"Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients","volume":"102","author":"Ghermezi","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2023.01.006_bib0008","doi-asserted-by":"crossref","first-page":"62490","DOI":"10.18632\/oncotarget.11519","article-title":"Soluble PD-L1: a biomarker to predict progression of autologous transplantation in patients with multiple myeloma","volume":"7","author":"Huang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.exphem.2023.01.006_bib0009","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1038\/leu.2014.137","article-title":"High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-cell lymphoma: results from a French multicenter clinical trial","volume":"28","author":"Rossille","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2023.01.006_bib0010","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1182\/blood-2011-03-340885","article-title":"Soluble IL-2R\u03b1 facilitates IL-2-mediated immune responses and predicts reduced survival in follicular B-cell non-Hodgkin lymphoma","volume":"118","author":"Yang","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2023.01.006_bib0011","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3390\/cancers13020279","article-title":"Immune functions of signaling lymphocytic activation molecule family molecules in multiple myeloma","volume":"13","author":"Ishibashi","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.exphem.2023.01.006_bib0012","doi-asserted-by":"crossref","first-page":"34784","DOI":"10.18632\/oncotarget.26196","article-title":"Clinical impact of serum soluble SLAMF7 in multiple myeloma","volume":"9","author":"Ishibashi","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.exphem.2023.01.006_bib0013","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41375-019-0525-6","article-title":"Soluble SLAMF7 promotes the growth of myeloma cells via homophilic interaction with surface SLAMF7","volume":"34","author":"Kikuchi","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2023.01.006_bib0014","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1158\/1078-0432.CCR-08-0501","article-title":"Functional B7.2 and B7-H2 molecules on myeloma cells are associated with a growth advantage","volume":"15","author":"Yamashita","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2023.01.006_bib0015","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/35105024","article-title":"T-cell regulation by CD28 and CTLA-4","volume":"1","author":"Alegre","year":"2001","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.exphem.2023.01.006_bib0016","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1600-065X.2009.00770.x","article-title":"CD28 and CTLA-4 coreceptor expression and signal transduction","volume":"229","author":"Rudd","year":"2009","journal-title":"Immunol Rev"},{"key":"10.1016\/j.exphem.2023.01.006_bib0017","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.eururo.2015.02.032","article-title":"A systematic review of immunotherapy in urologic cancer: evolving roles for targeting of CTLA-4, PD-1\/PD-L1, and HLA-G","volume":"68","author":"Carosella","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.exphem.2023.01.006_bib0018","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3390\/cells11030320","article-title":"Immune checkpoint inhibitors in non-small cell lung cancer: progress, challenges, and prospects","volume":"11","author":"Tang","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.exphem.2023.01.006_bib0019","first-page":"1168","article-title":"Expression of costimulatory molecules in human leukemias","volume":"10","author":"Hirano","year":"1996","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2023.01.006_bib0020","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1046\/j.1365-2141.1998.00901.x","article-title":"The expression of co-stimulatory molecules and their relationship to the prognosis of human acute myeloid leukaemia: poor prognosis of B7-2-positive leukaemia","volume":"102","author":"Maeda","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2023.01.006_bib0021","doi-asserted-by":"crossref","first-page":"5708","DOI":"10.1158\/1078-0432.CCR-04-2672","article-title":"Expression of functional B7-H2 and B7.2 costimulatory molecules and their prognostic implications in de novo acute myeloid leukemia","volume":"11","author":"Tamura","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2023.01.006_bib0022","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1182\/blood.V96.4.1274","article-title":"B7-2-positive myeloma: incidence, clinical characteristics, prognostic significance, and implications for tumor immunotherapy","volume":"96","author":"Pope","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2023.01.006_bib0023","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/sj.leu.2402466","article-title":"Human plasma contains a soluble form of CD86 which is present at elevated levels in some leukaemia patients","volume":"16","author":"Hock","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2023.01.006_bib0024","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/leu.2008.291","article-title":"Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma","volume":"23","author":"Kyle","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2023.01.006_bib0025","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1158\/1541-7786.MCR-19-0391","article-title":"SLAMF3-mediated signaling via ERK pathway activation promotes aggressive phenotypic behaviors in multiple myeloma","volume":"18","author":"Ishibashi","year":"2020","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.exphem.2023.01.006_bib0026","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S1074-7613(00)00030-3","article-title":"Soluble CD86 is a costimulatory molecule for human T lymphocytes","volume":"13","author":"Jeannin","year":"2000","journal-title":"Immunity"},{"key":"10.1016\/j.exphem.2023.01.006_bib0027","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.exphem.2023.01.006_bib0028","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1002\/cncr.11693","article-title":"The clinical significance of soluble CD86 levels in patients with acute myeloid leukemia and myelodysplastic syndrome","volume":"98","author":"Hock","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.exphem.2023.01.006_bib0029","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1365-2141.2006.05983.x","article-title":"Circulating levels and clinical significance of soluble CD86 in myeloma patients","volume":"133","author":"Hock","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2023.01.006_bib0030","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.molcel.2019.09.017","article-title":"Alternative splicing regulatory networks: functions, mechanisms, and evolution","volume":"76","author":"Ule","year":"2019","journal-title":"Mol Cell"},{"key":"10.1016\/j.exphem.2023.01.006_bib0031","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nature08909","article-title":"Expansion of the eukaryotic proteome by alternative splicing","volume":"463","author":"Nilsen","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2023.01.006_bib0032","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41392-021-00486-7","article-title":"Alternative splicing and cancer: a systematic review","volume":"6","author":"Zhang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.exphem.2023.01.006_bib0033","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1146\/annurev.immunol.14.1.233","article-title":"CD28\/B7 system of T cell costimulation","volume":"14","author":"Lenschow","year":"1996","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.exphem.2023.01.006_bib0034","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/ni1124","article-title":"CD28 induces immunostimulatory signals in dendritic cells via CD80 and CD86","volume":"5","author":"Orabona","year":"2004","journal-title":"Nat Immunol"},{"key":"10.1016\/j.exphem.2023.01.006_bib0035","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1046\/j.1365-2567.2000.00121.x","article-title":"CD28, CTLA-4 and their ligands: who does what and to whom?","volume":"101","author":"Sansom","year":"2000","journal-title":"Immunology"},{"key":"10.1016\/j.exphem.2023.01.006_bib0036","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.4049\/jimmunol.152.4.1618","article-title":"Role of IL-6, IL-1, and CD28 signaling in responses of mouse CD4+ T cells to immobilized anti-TCR monoclonal antibody","volume":"152","author":"Holsti","year":"1994","journal-title":"J Immunol"},{"key":"10.1016\/j.exphem.2023.01.006_bib0037","doi-asserted-by":"crossref","first-page":"5002","DOI":"10.1182\/blood-2006-03-012542","article-title":"CD28-mediated regulation of multiple myeloma cell proliferation and survival","volume":"109","author":"Bahlis","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2023.01.006_bib0038","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.4049\/jimmunol.1100016","article-title":"CD28 expressed on malignant plasma cells induces a prosurvival and immunosuppressive microenvironment","volume":"187","author":"Nair","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.exphem.2023.01.006_bib0039","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1084\/jem.20110040","article-title":"Sustained antibody responses depend on CD28 function in bone marrow-resident plasma cells","volume":"208","author":"Rozanski","year":"2011","journal-title":"J Exp Med"},{"key":"10.1016\/j.exphem.2023.01.006_bib0040","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1182\/blood-2013-10-530964","article-title":"CD28-mediated pro-survival signaling induces chemotherapeutic resistance in multiple myeloma","volume":"123","author":"Murray","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2023.01.006_bib0041","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/nri3108","article-title":"The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses","volume":"11","author":"Walker","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.exphem.2023.01.006_bib0042","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1006\/cimm.2001.1784","article-title":"Codelivery of DNA coding for the soluble form of CD86 results in the down-regulation of the immune response to DNA vaccines","volume":"209","author":"Fl\u00f3","year":"2001","journal-title":"Cell Immunol"},{"key":"10.1016\/j.exphem.2023.01.006_bib0043","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.600000","article-title":"CD86 Is a selective CD28 ligand supporting FoxP3+ regulatory T cell homeostasis in the presence of high levels of CTLA-4","volume":"11","author":"Halliday","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.exphem.2023.01.006_bib0044","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1007\/s00262-014-1589-9","article-title":"FOXP3 and CTLA4 overexpression in multiple myeloma bone marrow as a sign of accumulation of CD4+ T regulatory cells","volume":"63","author":"Braga","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.exphem.2023.01.006_bib0045","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/bjc.2011.575","article-title":"The frequency of T regulatory cells modulates the survival of multiple myeloma patients: detailed characterisation of immune status in multiple myeloma","volume":"106","author":"Giannopoulos","year":"2012","journal-title":"Br J Cancer"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X23000292?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X23000292?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:38:05Z","timestamp":1759567085000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X23000292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":45,"alternative-id":["S0301472X23000292"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2023.01.006","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The levels of serum soluble CD86 are correlated with the expression of CD86 variant 3 gene and are prognostic indicators in patients with myeloma","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2023.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 ISEH \u2013 Society for Hematology and Stem Cells. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}